FTSE 100 news / Companies and sectors / Haleon
Haleon news analysis
Haleon (LSE: HLN) is in the FTSE 100. 17 of the last 21 days had relevant coverage.
Latest: Tuesday 20 October 2026
+3.5 from 2 relevant stories. Coverage was limited to Haleon launching a one-day interactive wellness pop-up in Toronto, called Haleon Health House. It is a small brand-building story, so the lean is only mildly positive.
Tone over time
Coverage of Haleon improved between 30 September 2026 and 20 October 2026
Daily news tone, from −10 (clearly bad) to +10 (clearly good). Gaps are days with no relevant stories.
Tone rose -0.5-fold from −7 to 4 between 30 Sep and 20 Oct. Its low was −8 in 7 Oct.
- 11
- 22
- 33
9 days of 17 had fewer than 3 relevant stories, so those points are thin evidence. Numbered markers are the days with the strongest single headline (key below). This is the tone of coverage, not a share price.Source: MarketFrame news analysis
| day | Tone |
|---|---|
| 30 Sep | −7 |
| 1 Oct | −2 |
| 2 Oct | −5 |
| 3 Oct | – |
| 4 Oct | 2 |
| 5 Oct | 2 |
| 6 Oct | −6 |
| 7 Oct | −8 |
| 8 Oct | 2 |
| 9 Oct | −3 |
| 10 Oct | −1 |
| 11 Oct | – |
| 12 Oct | – |
| 13 Oct | 2 |
| 14 Oct | 5 |
| 15 Oct | 6 |
| 16 Oct | −2 |
| 17 Oct | 3 |
| 18 Oct | – |
| 19 Oct | 7 |
| 20 Oct | 4 |
Day by day
| Day | Tone | Stories | What the coverage was about |
|---|---|---|---|
| Tuesday 20 October 2026 | +3.5 | 2 | Coverage was limited to Haleon launching a one-day interactive wellness pop-up in Toronto, called Haleon Health House. |
| Monday 19 October 2026 | +7.0 | 5 | Coverage focused on Haleon's results helped by Sensodyne and oral health strength, ahead of a Q3 update. |
| Sunday 18 October 2026 | – | 0 | |
| Saturday 17 October 2026 | +2.8 | 4 | Coverage focused on Haleon's oral health business supporting its dividend, alongside the appointment of Deep Malde to lead expert marketing and transformation. |
| Friday 16 October 2026 | −2.3 | 4 | Coverage was mixed, with an analyst downgrade and a trimmed UBS growth forecast weighing on sentiment. |
| Thursday 15 October 2026 | +5.5 | 3 | Coverage was mildly positive, with commentary on Sensodyne helping the latest results and a valuation piece calling the shares undervalued on cash flow. |
| Wednesday 14 October 2026 | +4.5 | 2 | Coverage of Haleon was mainly valuation commentary and a push behind its Excedrin brand. |
| Tuesday 13 October 2026 | +2.3 | 7 | Coverage mixed a run of share price gains and several brand campaigns for Excedrin and Robitussin with a UBS view that Haleon may dial back its FY26 growth target. |
| Monday 12 October 2026 | – | 0 | |
| Sunday 11 October 2026 | – | 0 | |
| Saturday 10 October 2026 | −1.2 | 2 | Coverage was mixed: a new gum health study was presented as long-term upside in oral care, while JPMorgan's negative catalyst watch drew scrutiny to the shares. |
| Friday 9 October 2026 | −2.8 | 2 | Coverage centred on JPMorgan trimming its price target for Haleon, which leans negative. |
| Thursday 8 October 2026 | +2.3 | 4 | Coverage focused on Haleon's oral care trials against Colgate and a new Otrivin brand campaign, which lean mildly positive. |
| Wednesday 7 October 2026 | −7.7 | 2 | Coverage of Haleon was negative, with JPMorgan cutting its price target to 295p and the shares slipping on growth worries ahead of the company's update. |
| Tuesday 6 October 2026 | −5.7 | 7 | Coverage was mainly about JPMorgan cutting its price target on Haleon from 315p to 295p and placing it on negative watch ahead of Q3 results. |
| Monday 5 October 2026 | +2.0 | 2 | Coverage was about Haleon appointing Vandana Chamaria as Head of Oral Health for India and South Asia. |
| Sunday 4 October 2026 | +1.8 | 2 | Coverage was limited to the appointment of Vandana Chamaria as Head of Oral Health, South Asia. |
| Saturday 3 October 2026 | – | 0 | |
| Friday 2 October 2026 | −5.0 | 6 | Coverage was mostly about Haleon's shares slipping after JPMorgan put it on negative catalyst watch, with targets cut and growth worries ahead of the Q3 update. |
| Thursday 1 October 2026 | −2.0 | 1 | The only relevant coverage asked whether investors are rotating away from Haleon and other defensive shares as bond yields ease and the FTSE 100 trades higher. |
| Wednesday 30 September 2026 | −6.8 | 2 | Coverage centred on JPMorgan cutting its price target on Haleon, with the shares falling as a result. |
Sector: Pharma and healthcare